Nivagen is engaged in the development, acquisition and sales of generic prescription drugs and over the counter products for the North American market. Our vision is to deliver high quality products at affordable prices by leveraging global partnerships with the best FDA approved manufacturing facilities across the world.
Our sales and marketing personnel are among the best in the world. The US generic prescription market is currently at approximately $60 billion, and over $120 billion's worth of products will be coming off of patent protection in next 10 years. Nivagen believes that, with its strategic partnership model of global alliances with highly efficient pharmaceutical companies across the globe, we can provide cost savings to the consumer while creating value for all members of the supply chain.
Nivagen is focused in three areas of product development: development/co-development, acquisition/in-licensing, and providing sales and marketing services. We are actively looking to partner with CRO and CRAM to co-develop products. We are also acquiring existing products. If you are small FDA qualified manufacturer and want to launch your company or product in the US, Nivagen can provide complete turnkey solutions and cost effective delivery on an accelerated timeline.
Our sales and marketing personnel are among the best in the world. The US generic prescription market is currently at approximately $60 billion, and over $120 billion's worth of products will be coming off of patent protection in next 10 years. Nivagen believes that, with its strategic partnership model of global alliances with highly efficient pharmaceutical companies across the globe, we can provide cost savings to the consumer while creating value for all members of the supply chain.
Nivagen is focused in three areas of product development: development/co-development, acquisition/in-licensing, and providing sales and marketing services. We are actively looking to partner with CRO and CRAM to co-develop products. We are also acquiring existing products. If you are small FDA qualified manufacturer and want to launch your company or product in the US, Nivagen can provide complete turnkey solutions and cost effective delivery on an accelerated timeline.
Location: United States, California, Sacramento
Employees: 11-50
Total raised: $16M
Founded date: 2009
Investors 2
| Date | Name | Website |
| - | Telegraph ... | thpartners... |
| - | Corbel Cap... | corbelcap.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 20.05.2020 | - | $16M | - |
Mentions in press and media 5
| Date | Title | Description |
| 20.05.2025 | Persist AI: Revolutionizing Drug Development with Cloud Lab and $12 Million Funding | In the fast-paced world of pharmaceuticals, time is money. The race to bring new drugs to market is relentless. Enter Persist AI, a trailblazer in AI-driven robotics for pharmaceutical formulation development. Recently, the company announce... |
| 20.05.2025 | Persist AI: $12 Million Series A Raised And Cloud Lab Launched | Persist AI, a pioneer in AI-based robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), announced the launch of its Cloud Lab platform following the closing of an oversubscribed $12 million Se... |
| 20.05.2025 | Persist AI Launches Cloud Lab to Accelerate Pharmaceutical Formulation Development, Raises $12Million Series A Funding | AI-driven robotics platform reduces drug formulation development time from years to months Persist AI, a pioneer in AI-driven robotics for pharmaceutical formulation development and Chemistry, Manufacturing, and Controls (CMC), today announ... |
| 20.05.2020 | Nivagen Pharmaceuticals Raises $16M in Growth Equity Financing | Nivagen Pharmaceuticals, a Sacramento, CA-based specialty pharmaceuticals company, closed a $16m equity financing round. The round was led by Telegraph Hill Partners with participation from existing investors. The company intends to use the... |
| - | Nivagen Pharmaceuticals, Inc. | “Home | My Site” |